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OBJECTIVE: The objective of this study was to examine the effects of angiotensin-converting enzyme inhibitors on
peritoneal membrane transport, peritoneal protein loss, and proteinuria in peritoneal dialysis patients.
METHODS: Fifty-four peritoneal dialysis patients were included in the study. The patients were divided into two
groups. Group 1 (n=34) was treated with angiotensin-converting enzyme inhibitors. Group 2 (n=20) did not receive
any antihypertensive drugs during the entire follow-up. Eleven patients were excluded from the study thereafter.
Thus, a total of 30 patients in Group 1 and 13 patients in Group 2 completed the study. We observed the patients for
six months. Group 1 patients received maximal doses of angiotensin-converting enzyme inhibitors for six months.
Parameters at the beginning of study and at the end of six months were evaluated. ClinicalTrial.gov: NCT01575652.
RESULTS: At the end of six months, total peritoneal protein loss in 24-hour dialysate effluent was significantly
decreased in Group 1, whereas it was increased in Group 2. Compared to the baseline level, peritoneal albumin loss
in 24-hour dialysate effluent and 4-hour D/P creatinine were significantly increased in Group 2 but were not
significantly changed in Group 1. A covariance analysis between the groups revealed a significant difference only in
the decreased amount of total protein loss in 24-hour dialysate. Proteinuria was decreased significantly in Group 1.
CONCLUSION: This study suggests that angiotensin-converting enzyme inhibitors reduce peritoneal protein loss and
small-solute transport and effectively protect peritoneal membrane transport in peritoneal dialysis patients.
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Ever since peritoneal dialysis (PD) has been used in the
treatment of chronic kidney disease (CKD), high peritoneal
protein loss has been observed after each PD exchange. In
adult patients, the loss has been estimated at 6 to 13 g daily
(1). PD patients lose significant quantities of protein and
albumin during the dialysis procedure (2). Low serum
albumin has been associated with high peritoneal membrane
transport status and also correlates with mortality (3). Loss of
peritoneal function is a major complication associated with
long-term peritoneal dialysis. Changes observed include
loss and degeneration of the mesothelium, submesothelial
thickening, alterations in the structure and number of
blood vessels, and reduplication of the vascular basement
membrane (4).
The use of angiotensin-converting enzyme inhibitors
(ACE-Is) in kidney disease has been demonstrated to be
effective in reducing proteinuria and slowing the progression
of kidney disease. The main mechanism of the antiprotei-
nuric action of ACEIs is the reduction of the negative effects
of angiotensin II on kidney hemodynamics (5). ACE-Is can
preserve peritoneal histology, peritoneal function, and
mesothelial cell remodeling (6).
Based on these beneficial effects of ACE-Is on proteinuria,
we aimed to investigate the effects of ACE-Is on peritoneal
membrane transport, peritoneal protein loss, and protei-
nuria in patients being treated with PD.
PATIENTS AND METHODS
Study design and patients
This prospective cohort study was conducted at the Unit
of Nephrology of Sisli Etfal Education and Research
Hospital, Istanbul, Turkey. Prior to subject recruitment,
the study protocol was reviewed and approved by the local
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ethics committee in accordance with the ethical principles
for human investigations, and written informed consents
were obtained from all patients. Between June 2008 and
January 2009, 54 age- and gender-matched continuous
ambulatory peritoneal dialysis (CAPD) patients were
included in the study consecutively.
Patients were divided into two groups according to
decision of the physician: Group 1 (n= 34) consisted of
patients treated with ACE-Is, and Group 2 (n= 20) consisted
of patients not treated with ACE-Is. The inclusion criteria
were chronic PD patients between 18 and 85 years old who
had not received any antihypertensive drugs within the
previous 12 months. All patients were on a standard CAPD
program (2-2.5 L; 4 exchanges/day) without the use of
icodextrin. The exclusion criteria were as follows: patients
who had a history of antihypertensive treatment with ACE-Is
or angiotensin-receptor blockers or aldosterone antagonists
for the 12 months prior to the study time, intolerance to ACE-
Is, CAPD-related peritonitis within six months prior to or
during the study period, history of malignant hypertension
or hypertensive encephalopathy, or cerebrovascular accident
within the sixmonths prior to the study, chronic liver disease,
and recent acute illness and/or history of any overt chronic
inflammatory disease. We excluded four patients from
Group 1. One patient developed peritonitis during the study;
two patients could not tolerate the medication because of
hypotension and cough; one patient underwent renal
transplantation. In Group 2, seven patients were excluded.
Two patients developed peritonitis; two patients could not
tolerate the medication due to hypotension and cough; two
patients had uncontrolled hypertension; one patient did not
attend follow-up visits. Thus, 30 patients in Group 1 and 13
patients in Group 2 completed the six-month study. The type
of ACE-I prescribed to the patients was chosen randomly.
Group 1 patients received the maximum tolerated doses of
ACE-Is (such as lisinopril and perindopril) for six months.
Baseline definitions, measurements, and
biochemical analysis
Demographic variables, including the etiology of CKD,
age, and gender, were obtained from patients’ clinical
charts. All blood samples were taken after 10 hours of
overnight fasting. Serum urea, creatinine, and albumin
levels were analyzed. Creatinine clearance [(CCr) dialysate,
urine, and total] and Kt/V (dialysate, urine, and total) were
calculated weekly. Daily volumes (UF), 24-hour protein, and
albumin losses (dialysate, urine) were also recorded.
Parameters at the beginning of study and at the end of the
sixth month were evaluated. During the study, the dialysis
regime remained the same for all patients. In both groups,
we analyzed blood, 24-hour urine (in patients with residual
diuresis .100 mL daily), and peritoneal effluent fluid at 4-
and 24-hour dwell times. Peritoneal effluent fluid at the 24-
hour dwell time was used to determine total protein,
albumin, urea and creatinine. The urea kinetic test in closest
proximity to the time of the peritoneal equilibration test
(PET) was used in the analysis.
After the subject had rested in the supine position for at
least 15 minutes, blood pressure was measured with a
standard mercury sphygmomanometer three times with
the cuff around the right arm. Patients’ blood pressure
measurements were taken on a regular basis every month.
The mean values were calculated. All patients were on
a standard 35-cal/kg/day carbohydrate, 1-2 g/kg/day
protein, and salt-restricted diet. Patients did not use essen-
tial amino acids and peritoneal dialysis solutions containing
amino acids. Serum urea, creatinine, and albumin levels
were assessed by enzymatic colorimetric assay. Dialysate
adequacy (Kt/V urea: dialysis and residual) and peritoneal
transport (4-hour D/PCr) were measured using standard
procedures (PD Adequest 1.4, 1994: Baxter Healthcare
Corporation, Deerfield, IL, USA). Dialysate albumin loss
was measured with the Bromo CresolGreen (BCG) method.
Dialysate total protein loss was measured with the Biuret
method. Urine protein concentration was determined with
an immunoturbidimetric method.
Statistical analysis
Statistical analysis was performed using the SPSS 13.0
software package (SPSS Inc., Chicago, IL, USA). Kolmogorov-
Smirnov tests were used to test the normality of data
distribution. The data were expressed as arithmetic means
and standard deviations. The chi-squared test was used to
compare the categorical variables between groups. Inde-
pendent sample T-tests and Mann-Whitney U tests were used
between groups for normally and abnormally distributed
continuous variables, respectively. Paired t-tests and Wilco-
xon signed-rank testswere used to analyze changes within each
group. A two-sided p-value ,0.05 was considered to be
statistically significant.
RESULTS
The baseline clinical, laboratory, and demographic char-
acteristics of patients are presented in Table 1. There were
Table 1 - Patient Characteristics.
Group 1 (n= 30) Group 2 (n= 13)
Gender (Male/Female) 18/12 6/7
Age (years) 38.4¡20 42¡16.4
Mean duration of PD
(months)
21.3¡15.6 18.2¡15.8
Weekly Kt/V urea 2.15¡0.43 2.21¡0.32
Weekly CCr * 64.97¡13.6 52.3¡14.2
Systolic BP (mmHg)* 125¡18.7 110.7¡21.7
Diastolic BP (mmHg)* 76¡10.3 64.6¡15.6
Serum albumin (g/dl) 3.7¡0.3 3.8¡0.34







Proteinuria (mg/day) 470¡662 129.7¡187.8






Diabetic nephropathy 5 16.7 2 15.38
Chronic
glomerulonephritis
3 10 3 23.07
Chronic pyelonephritis 3 10 2 15.38
Polycystic renal disease 3 10 - -
Obstructive nephropathy 2 6.7 - -
Drug use 2 6.7 - -
Amyloidosis 1 3.3 3 23.07
Unknown 11 36.6 3 23.07
All values are given as the means ¡ standard deviations. NS: non-
significant, CCr: creatinine clearance, BP: blood pressure, D/P: dialysate/
plasma, UF: daily volumes.
*p,0.05.
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no significant differences in gender, age, or mean duration
of PD between groups (p.0.05 for all) (Table 1). After six
months, the decreases in systolic and diastolic blood
pressures were statistically significant in Group 1 but not
in Group 2. Only the decrease in peritoneal total protein
loss at 24 hours of dwell time was significant following
ACE-Is treatment (p,0.001). Statistically significant differ-
ences were not identified in comparisons of the other
studied parameters (p.0.05) (Table 2, Figures 1A, 1B, 3A).
In Group 2, at the end of six months, 4-hour D/P creatinine
and peritoneal albumin losses at 24 hours of dwell time
were increased significantly. Other parameters did not
change significantly in Group 2 (p.0.05) (Table 3,
Figures 2A, 2B, 3B).
After ACE-Is were added to the treatment of the PD
patients in Group 1, proteinuria levels were reduced
significantly (p= 0.011). Three patients became anuric; thus,
the total number of anuric patients increased to twelve at
the end of study. Residual renal function was surprisingly
increased in eight patients at the end of six months and was
decreased in ten patients. In total, the residual renal
function decreased in Group 1, but this difference was not
statistically significant (p.0.05) (Table 2). In Group 2,
proteinuria levels did not change significantly during the
study period (p.0.05). Three patients became anuric,
Table 2 - The effects of ACE-I treatment on the measured
parameters in Group 1.
Parameter Baseline
At the end of
six months p-value
Weekly Kt/V urea 2.15¡0.43 2.16¡0.46 NS
Weekly CCr 64.97¡13.6 69.5¡30. NS
Systolic BP (mmHg) 125¡18.7 111¡23.74 0.001
Diastolic BP (mmHg) 76¡10.3 70¡11.4 0.003
Serum albumin (g/dl) 3.7¡0.3 3.74¡0.4 NS
24-hour peritoneal UF (ml) 1330¡483 1413¡689 NS
4-hour peritoneal UF (ml) 455¡185 468¡178 NS
Proteinuria (mg/day) 470¡662 224¡362 0.011
Diuresis (ml/day) 453¡539 392¡574 NS
All values are given as the means ¡ standard deviations. NS: non-
significant, CCr: creatinine clearance, BP: blood pressure, UF: daily
volumes.
Figure 1 - A. Total Loss of Protein in Group 1. B. Total Loss of Albumin in Group 1.
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increasing the number of anuric patients to ten in Group 2 at
the end of six months. In addition, residual renal function
was decreased in two patients, whereas it was increased in
one patient. Overall, the residual renal function was also
decreased, but this difference was not statistically signifi-
cant (p.0.05) (Table 3).
Covariance analysis between groups revealed a signifi-
cant difference only in the amount of total protein loss in 24-
hour dialysate in favor of reduction (p= 0.048) in Group 1.
No adverse effects, including hyperkalemia, were observed.
DISCUSSION
This study demonstrates that treatment with ACE-Is may
preserve peritoneal membrane transport and may reduce
peritoneal total protein loss and proteinuria in patients with
PD.
ACE-Is affect the peritoneal membrane by increasing
convective transport and decreasing diffusive transport—
although in a limited way—and significantly reducing
peritoneal protein losses at both 4-hour and 24-hour dwell
times. The mechanisms of action of these effects have not
been clearly described; however, they may be related to an
effect on the permeability of the peritoneal membrane
capillaries, where ACE-Is may act directly or indirectly by
blocking the renin–angiotensin–aldosterone system (7).
Figure 2 - A. Total Loss of Protein in Group 2. B. Total Loss of Albumin in Group 2.
Table 3 - The parameters of untreated patients in Group
2.
Parameter Baseline
At the end of
six months p-value
Weekly Kt/V urea 2.21¡0.32 2.32¡0.55 NS
Weekly CCr 52.3¡14.2 59.8¡16.05 NS
Systolic BP (mmHg) 110.7¡21.7 111.5¡21.5 NS
Diastolic BP (mmHg) 64.6¡15.6 67.6¡15.3 NS
Serum albumin (g/dl) 3.8¡0.34 3.79¡0.43 NS
24-hour peritoneal UF (ml) 1298¡477 1303¡500 NS
4-hour peritoneal UF (ml) 465¡97.4 465¡129 NS
Proteinuria (mg/day) 129.7¡187.8 113¡225 NS
Diuresis (ml/day) 211¡270 79.1¡218 NS
All values are given as the means ¡ standard deviations. NS: non-
significant, CCr: creatinine clearance, BP: blood pressure, UF: daily
volumes.
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Coronel et al. (8) demonstrated that captopril reduced
peritoneal albumin loss without a significant change in
systemic blood pressure. This effect likely decreases
capillary permeability, either by a direct action of the drug
or indirectly, mediated by AII, prostaglandins, or kinins.
Jearnsujitwimol et al. (9) demonstrated that candesartan
could provide a nutritional benefit by attenuating peritoneal
loss of albumin and mediates an effective antihypertensive
action. In addition, Agraharkar et al. (10) investigated the
effect of RAS blockage on peritoneal protein loss in PD
patients. These authors concluded that RAS blockage did
not reduce protein loss into the peritoneal fluid during
dialysis. In our study, peritoneal total protein loss was
significantly reduced in patients treated with ACE-Is.
However, peritoneal albumin loss did not change signifi-
cantly. Additionally, peritoneal albumin loss increased
significantly in Group 2.
Serum albumin is correlated with dietary protein intake in
patients with renal disease. Peritoneal dialysis is associated
with albumin and amino acid losses in the spent dialysate,
which can reach 5–15 g/day. These losses may represent
,15% of the net daily protein intake (11). Kaysen GA et al.
(12) reported a strong correlation between serum albumin
level and peritoneal protein loss in 18 patients. Pollock CA
et al. (13) reported a weak correlation in 134 patients. This
correlation has not been confirmed in a number of other
studies (14,15). Plasma volume expansion should cause the
dilution of plasma proteins and a reduction in serum levels.
Volume expansion commonly occurs in chronic renal
failure, and the degree of fluid overload is associated with
the serum albumin concentration (16). In this study, serum
albumin concentrations were not significantly changed at
the end of six months of treatment with ACE-Is. Although
we did not evaluate the volume statuses of our patients, the
reason for the stable plasma albumin levels may have been
the increased plasma volume with no change in total
albumin mass in PD patients.
Long-term PD causes morphological changes in the
peritoneal membrane, including interstitial fibrosis, loss of
the mesothelial cell layer and vasculopathy. One of the
potential mechanisms of this damage is the presence of
a local renin-angiotensin-aldosterone system (RAAS) by
which injured peritoneal mesothelial cell-derived angioten-
sin-II (AII) causes activations in TGF-b and VEGF expres-
sion and epithelial-to-mesenchymal transition (EMT), which
contribute to extracellular matrix accumulation and neoan-
giogenesis in submesothelial tissues. Duman et al. (17)
reported that by inhibiting the overexpression of cytokines
(i.e., TGFb1 and VEGF), renin–angiotensin system blockade
ameliorates the peritoneal injury induced by the hypertonic
Figure 3 - A. 4-hours D/P Creatinine of Group 1. B. 4-hours D/P Creatinine of Group 2.
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PD solution. In addition, these authors found that ACEIs or
AR blockers (or both) may preserve the viability of the
peritoneum in continuous ambulatory PD patients over long
periods.
The oral administration of enalapril ameliorates changes
in peritoneal function and morphology (18), and the oral
administration of lisinopril (an ACEI) and valsartan (an AR
blocker) has similar beneficial effects on peritoneal function
and morphology (19). Multiple studies have shown that
ACE-Is prevent peritoneal protein loss (8,9). As a result,
ACE-Is have a potential beneficial effect on the prevention
of peritoneal fibrosis. Based on these findings, ACE-Is may
preserve the viability of the peritoneum in PD patients over
the long term.
In PD, both in vivo and in vitro studies involving the
effects of ACE-Is on peritoneal membrane transporters
have yielded different results. Kolesnyk et al. (20) have
shown that treatment with ACEI/ARB in PD patients may
prevent or retard the increase in D/P creatinine that
occurs during long-term PD. In contrast, Jearnsujitwimol
et al. (9) demonstrated that candesartan at a dose of 8-
16 mg/day could effectively control blood pressure but
caused no changes in peritoneal transport characteristics.
We showed that peritoneal transport was not significantly
decreased in Group 1 and was significantly increased in
Group 2. The results of this study indicate that treatment
with ACE-I in PD patients is likely to have a membrane-
protective effect by preventing the increase in small-solute
transport. Long-term treatment with ACE-Is attenuates the
peritoneal alterations that can develop in long-term PD
patients.
Ultrafiltration failure in patients undergoing PD is a
condition with an incidence that increases over time. This
complication is related to increased cardiovascular morbidity
and mortality and is a major cause of the abandonment of the
treatment technique (21). Duman et al. (17) demonstrated that
an ACE-I, enalapril, improved ultrafiltration capacity when
administered intraperitoneally. This ACE-I appeared to have
a slower rate of decline in ultrafiltration, effectively protect-
ing against peritoneal fibrosis in long-term peritoneal dialysis
(17). ACE-Is may have an important role in PD by affecting
the rate of decline of residual renal function in PD patients. Li
et al. (22) investigated the effect of ACE-Is on residual renal
function. Those authors concluded that the ACE-I ramipril
might reduce the rate of decline of residual renal function in
PD patients. At 12 months, 14 patients in the ramipril group
(n= 30) and 22 in the control group (n= 30) became anuric.
Two randomized controlled trials showed positive effects of
A-II inhibitors on residual glomerular filtration rate (rGFR)
in peritoneal dialysis patients (22,23). In another study,
Kolesnyk et al. (24) found no difference with respect to the
rate of decline of rGFR and time of the development of
anuria. In our study, there were no significant differences in
ultrafiltration volume and residual diuresis between groups,
although proteinuria was significantly decreased in Group 1
(p= 0.011). Therefore, the effect of ACE-Is may be important
in preserving peritoneal function and in preventing protein
losses, such as those experienced by PD patients, in whom
considerable quantities of proteins are lost through the
peritoneum and diuresis.
There are limitations in our study that must be consid-
ered. The study groups were not large or well matched due
to a limited number of patients. The follow-up period was
also short. The types and dosages of ACE-Is given to the
patients were not strictly standardized.
Our findings suggest that ACE inhibitors support a
decline in peritoneal protein losses and small-solute trans-
port and effectively protect peritoneal membrane transport
in long-term peritoneal dialysis.
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